Zhang Hang, Duan Chao-Jun, Chen Wei, Wang Shao-Qiang, Zhang Sheng-Kang, Dong Shuo, Cheng Yuan-Da, Zhang Chun-Fang
Department of Cardiothoracic Surgery Xiangya Hospital, Central South University, Changsha, China.
Asian Pac J Cancer Prev. 2012;13(5):2355-62. doi: 10.7314/apjcp.2012.13.5.2355.
The SH2B1 adaptor protein is recruited to multiple ligand-activated receptor tyrosine kinases that play important role in the physiologic and pathologic features of many cancers. The purpose of this study was to assess SH2B1 expression and to explore its contribution to the non-small cell lung cancer (NSCLC).
SH2B1 expression in 114 primary NSCLC tissue specimens was analyzed by immunohistochemistry and correlated with clinicopathological parameters and patients' outcome. Additionally, 15 paired NSCLC background tissues, 5 NSCLC cell lines and a normal HBE cell line were evaluated for SH2B1 expression by RT-PCR and immunoblotting, immunofluorescence being applied for the cell lines.
SH2B1 was found to be overexpressed in NSCLC tissues and NSCLC cell lines. More importantly, high SH2B1 expression was significantly associated with tumor grade, tumor size, clinical stage, lymph node metastasis, and recurrence respectively. Survival analysis demonstrated that patients with high SH2B1 expression had both poorer disease- free survival and overall survival than other patients. Multivariate Cox regression analysis revealed that SH2B1 overexpression was an independent prognostic factor for patients with NSCLC.
Our findings suggest that the SH2B1 protein may contribute to the malignant progression of NSCLC and could offer a novel prognostic indicator for patients with NSCLC.
SH2B1衔接蛋白被募集到多种配体激活的受体酪氨酸激酶，这些激酶在许多癌症的生理和病理特征中发挥重要作用。本研究的目的是评估SH2B1的表达，并探讨其在非小细胞肺癌（NSCLC）中的作用。
通过免疫组织化学分析114例原发性NSCLC组织标本中SH2B1的表达，并与临床病理参数和患者预后相关联。此外，通过RT-PCR和免疫印迹评估15对NSCLC背景组织、5种NSCLC细胞系和1种正常HBE细胞系中SH2B1的表达，对细胞系应用免疫荧光法。
发现SH2B1在NSCLC组织和NSCLC细胞系中过表达。更重要的是，高SH2B1表达分别与肿瘤分级、肿瘤大小、临床分期、淋巴结转移和复发显著相关。生存分析表明，SH2B1高表达的患者无病生存期和总生存期均比其他患者差。多因素Cox回归分析显示，SH2B1过表达是NSCLC患者的独立预后因素。
我们的研究结果表明，SH2B1蛋白可能促进NSCLC的恶性进展，并可为NSCLC患者提供一种新的预后指标。
